Unravelling the genomic targets of small molecules using high-throughput sequencing

Nature Reviews Genetics

Volumn 15, Issue 12, 2014, Pages 783-796

  Rodriguez, Raphaël ^a,b   Miller, Kyle M ^c  

^a CNRS   (France)

^b INSTITUT CURIE   (France)

^c UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 6 (1 THIANTHRENYL) 4 PYRANONE; 5 [4 (2 DIETHYLAMINOETHYLAMINO) 3 NITROPHENYL] 1,4 DIPHENYL 1,2,4 TRIAZOLIUM 3 THIOLATE; ANTINEOPLASTIC AGENT; APHIDICOLIN; C 646; CELL NUCLEUS DNA; CX 5461; EPZ 004777; EPZ 6438; ETOPOSIDE; GSK 126; GSK J 1; JIB 04; MI 30; ML 216; MM 401; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NSC 19630; NU 7441; ORY 1001; PTC 209; ROMIDEPSIN; RUXOLITINIB; SD 70; SEN 196; THIOSTREPTON; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VE 821; VORINOSTAT; MOLECULAR LIBRARY;

CHROMATIN; DEACETYLATION; DNA METHYLATION; DNA SEQUENCE; DRUG TARGETING; GENE FUNCTION; GENE REPLICATION; GENE TARGETING; HIGH THROUGHPUT SEQUENCING; HISTONE ACETYLATION; HISTONE DEMETHYLATION; HISTONE METHYLATION; HUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; REVIEW; ANIMAL; CHROMATIN IMMUNOPRECIPITATION; DRUG DELIVERY SYSTEM; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; GENETIC EPIGENESIS; GENETICS; MOLECULAR LIBRARY;

ANIMALS; CHROMATIN IMMUNOPRECIPITATION; DRUG DELIVERY SYSTEMS; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME-WIDE ASSOCIATION STUDY; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; SEQUENCE ANALYSIS, DNA; SMALL MOLECULE LIBRARIES;

EID: 84922336877     PISSN: 14710056     EISSN: 14710064     Source Type: Journal    
DOI: 10.1038/nrg3796     Document Type: Review

References (129)

1. Campos, E. I., & Reinberg, D. Histones: annotating chromatin. Annu. Rev. Genet. 43, 559-599 (2009
2. Kornberg, R. D. Chromatin structure: a repeating unit of histones and DNA. Science 184, 868-871 (1974
3. Bell, O., Tiwari, V. K., Thoma, N. H., & Schubeler, D. Determinants and dynamics of genome accessibility. Nature Rev. Genet. 12, 554-564 (2011
4. Jones, P. A. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nature Rev. Genet. 13, 484-492 (2012
5. Kouzarides, T. Chromatin modifications and their function. Cell 128, 693-705 (2007
6. Shogren-Knaak, M. et al. Histone H4-K16 acetylation controls chromatin structure and protein interactions. Science 311, 844-847 (2006
7. Arrowsmith, C. H., Bountra, C., Fish, P. V., Lee, K., & Schapira, M. Epigenetic protein families: a new frontier for drug discovery. Nature Rev. Drug Discov. 11, 384-400 (2012
8. Musselman, C. A., Lalonde, M. E., Cote, J., & Kutateladze, T. G. Perceiving the epigenetic landscape through histone readers. Nature Struct. Mol. Biol. 19, 1218-1227 (2012
9. Margueron, R., & Reinberg, D. Chromatin structure and the inheritance of epigenetic information. Nature Rev. Genet. 11, 285-296 (2010
10. Dervan, P. B. Molecular recognition of DNA by small molecules. Bioorg. Med. Chem. 9, 2215-2235 (2001
11. Miller, K. M., & Rodriguez, R. G-quadruplexes: selective DNA targeting for cancer therapeutics Expert Rev. Clin. Pharmacol. 4, 139-142 (2011
12. Dawson, M. A., & Kouzarides, T. Cancer epigenetics: from mechanism to therapy. Cell 150, 12-27 (2012
13. Dawson, M. A., Kouzarides, T., & Huntly, B. J. Targeting epigenetic readers in cancer. N. Engl. J. Med. 367, 647-657 (2012
14. Helin, K., & Dhanak, D. Chromatin proteins and modifications as drug targets. Nature 502, 480-488 (2013
15. Zhou, V. W., Goren, A., & Bernstein, B. E. Charting histone modifications and the functional organization of mammalian genomes. Nature Rev. Genet. 12, 7-18 (2011
16. Koboldt, D. C., Steinberg, K. M., Larson, D. E., Wilson, R. K., & Mardis, E. R. The next-generation sequencing revolution and its impact on genomics. Cell 155, 27-38 (2013
17. Barski, A. et al. High-resolution profiling of histone methylations in the human genome. Cell 129, 823-837 (2007
18. Johnson, D. S., Mortazavi, A., Myers, R. M., & Wold, B. Genome-wide mapping of in vivo protein-DNA interactions. Science 316, 1497-1502 (2007
19. Mikkelsen, T. S. et al. Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Nature 448, 553-560 (2007
20. Baylin, S. B., & Jones, P. A. A decade of exploring the cancer epigenome - biological and translational implications. Nature Rev. Cancer 11, 726-734 (2011
21. Bernstein, B. E. et al. An integrated encyclopedia of DNA elements in the human genome. Nature 489, 57-74 (2012
22. Plass, C. et al. Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer. Nature Rev. Genet. 14, 765-780 (2013
23. Xhemalce, B. From histones to RNA: role of methylation in cancer. Brief Funct. Genomics 12, 244-253 (2013
24. Anders, L. et al. Genome-wide localization of small molecules. Nature Biotech. 32, 92-96 (2014
25. Greer, E. L., & Shi, Y. Histone methylation: a dynamic mark in health, disease and inheritance. Nature Rev. Genet. 13, 343-357 (2012
26. Probst, A. V., Dunleavy, E., & Almouzni, G. Epigenetic inheritance during the cell cycle. Nature Rev. Mol. Cell Biol. 10, 192-206 (2009
27. Maze, I., Noh, K. M., Soshnev, A. A., & Allis, C. D. Every amino acid matters: essential contributions of histone variants to mammalian development and disease. Nature Rev. Genet. 15, 259-271 (2014
28. Mercer, T. R., Dinger, M. E., & Mattick, J. S. Long non-coding RNAs: insights into functions. Nature Rev. Genet. 10, 155-159 (2009
29. Patel, D. J., Phan, A. T., & Kuryavyi, V. Human telomere, oncogenic promoter and 5?-UTR G-quadruplexes: diverse higher order DNA and RNA targets for cancer therapeutics. Nucleic Acids Res. 35, 7429-7455 (2007
30. Belotserkovskii, B. P., Mirkin, S. M., & Hanawalt, P. C. DNA sequences that interfere with transcription: implications for genome function and stability. Chem. Rev. 113, 8620-8637 (2013
31. Yoo, C. B., & Jones, P. A. Epigenetic therapy of cancer: past, present and future. Nature Rev. Drug Discov. 5, 37-50 (2006
32. Smith, K. T., & Workman, J. L. Histone deacetylase inhibitors: anticancer compounds. Int. J. Biochem. Cell Biol. 41, 21-25 (2009
33. Kelly, T. K., De Carvalho, D. D., & Jones, P. A. Epigenetic modifications as therapeutic targets. Nature Biotech. 28, 1069-1078 (2010
34. Furey, T. S. ChIP-seq and beyond: new and improved methodologies to detect and characterize protein-DNA interactions. Nature Rev. Genet. 13, 840-852 (2012
35. Kopka, M. L., Yoon, C., Goodsell, D., Pjura, P., & Dickerson, R. E. The molecular origin of DNA-drug specificity in netropsin and distamycin. Proc. Natl Acad. Sci. USA 82, 1376-1380 (1985
36. Dervan, P. B. Design of sequence-specific DNA-binding molecules. Science 232, 464-471 (1986
37. Gottesfeld, J. M., Neely, L., Trauger, J. W., Baird, E. E., & Dervan, P. B. Regulation of gene expression by small molecules. Nature 387, 202-205 (1997
38. Meier, J. L., Yu, A. S., Korf, I., Segal, D. J., & Dervan, P. B. Guiding the design of synthetic DNA-binding molecules with massively parallel sequencing. J. Am. Chem. Soc. 134, 17814-17822 (2012
39. Huppert, J. L., & Balasubramanian, S. Prevalence of quadruplexes in the human genome. Nucleic Acids Res. 33, 2908-2916 (2005
40. Lipps, H. J., & Rhodes, D. G-quadruplex structures: in vivo evidence and function. Trends Cell Biol. 19, 414-422 (2009
41. Bochman, M. L., Paeschke, K., & Zakian, V. A. DNA secondary structures: stability and function of G-quadruplex structures. Nature Rev. Genet. 13, 770-780 (2012
42. Maizels, N., & Gray, L. T. The G4 genome. PLoS Genet. 9, e1003468 (2013
43. Balasubramanian, S., Hurley, L. H., & Neidle, S. Targeting G-quadruplexes in gene promoters: a novel anticancer strategy? Nature Rev. Drug Discov. 10, 261-275 (2011
44. Siddiqui-Jain, A., Grand, C. L., Bearss, D. J., & Hurley, L. H. Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c-MYC transcription. Proc. Natl Acad. Sci. USA 99, 11593-11598 (2002
45. Rodriguez, R. et al. A novel small molecule that alters shelterin integrity and triggers a DNA-damage response at telomeres. J. Am. Chem. Soc. 130, 15758-15759 (2008
46. Rodriguez, R. et al. Small-molecule-induced DNA damage identifies alternative DNA structures in human genes. Nature Chem. Biol. 8, 301-310 (2012
47. Muller, S., Kumari, S., Rodriguez, R., & Balasubramanian, S. Small-molecule-mediated G-quadruplex isolation from human cells. Nature Chem. 2, 1095-1098 (2010
48. Kolb, H. C., Finn, M. G., & Sharpless, K. B. Click chemistry: diverse chemical function from a few good reactions. Angew. Chem. Int. Ed Engl. 40, 2004-2021 (2001
49. Rostovtsev, V. V., Green, L. G., Fokin, V. V., & Sharpless, K. B. A stepwise huisgen cycloaddition process: copper(I)-catalyzed regioselective "ligation" of azides and terminal alkynes. Angew. Chem. Int. Ed Engl. 41, 2596-2599 (2002
50. Nitiss, J. L. Targeting DNA topoisomerase II in cancer chemotherapy. Nature Rev. Cancer 9, 338-350 (2009
51. Jackson, S. P., & Bartek, J. The DNA-damage response in human biology and disease. Nature 461, 1071-1078 (2009
52. Deal, R. B., Henikoff, J. G., & Henikoff, S. Genome-wide kinetics of nucleosome turnover determined by metabolic labeling of histones. Science 328, 1161-1164 (2010
53. Gaulton, K. J. et al. A map of open chromatin in human pancreatic islets. Nature Genet. 42, 255-259 (2010
54. Pang, B. et al. Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin. Nature Commun. 4, 1908 (2013
55. Yang, F., Kemp, C. J., & Henikoff, S. Doxorubicin enhances nucleosome turnover around promoters. Curr. Biol. 23, 782-787 (2013
56. Azarova, A. M. et al. Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. Proc. Natl Acad. Sci. USA 104, 11014-11019 (2007
57. Haffner, M. C. et al. Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nature Genet. 42, 668-675 (2010
58. Cowell, I. G. et al. Model for MLL translocations in therapy-related leukemia involving topoisomerase II?-mediated DNA strand breaks and gene proximity. Proc. Natl Acad. Sci. USA 109, 8989-8994 (2012
59. Dykhuizen, E. C. et al. BAF complexes facilitate decatenation of DNA by topoisomerase II?. Nature 497, 624-627 (2013
60. Mabb, A. M., Judson, M. C., Zylka, M. J., & Philpot, B. D. Angelman syndrome: insights into genomic imprinting and neurodevelopmental phenotypes. Trends Neurosci. 34, 293-303 (2011
61. Huang, H. S. et al. Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons. Nature 481, 185-189 (2012
62. King, I. F. et al. Topoisomerases facilitate transcription of long genes linked to autism. Nature 501, 58-62 (2013
63. Bester, A. C. et al. Nucleotide deficiency promotes genomic instability in early stages of cancer development. Cell 145, 435-446 (2011
64. Burrell, R. A. et al. Replication stress links structural and numerical cancer chromosomal instability. Nature 494, 492-496 (2013
65. Barlow, J. H. et al. Identification of early replicating fragile sites that contribute to genome instability. Cell 152, 620-632 (2013
66. Crosetto, N. et al. Nucleotide-resolution DNA double-strand break mapping by next-generation sequencing. Nature Methods 10, 361-365 (2013
67. Myatt, S. S., & Lam, E. W. The emerging roles of forkhead box (Fox) proteins in cancer. Nature Rev. Cancer 7, 847-859 (2007
68. Hegde, N. S., Sanders, D. A., Rodriguez, R., & Balasubramanian, S. The transcription factor FOXM1 is a cellular target of the natural product thiostrepton. Nature Chem. 3, 725-731 (2011
69. Sanders, D. A., Ross-Innes, C. S., Beraldi, D., Carroll, J. S., & Balasubramanian, S. Genome-wide mapping of FOXM1 binding reveals co-binding with estrogen receptor ? in breast cancer cells. Genome Biol. 14, R6 (2013
70. Chen, X. et al. The forkhead transcription factor FOXM1 controls cell cycle-dependent gene expression through an atypical chromatin binding mechanism. Mol. Cell. Biol. 33, 227-236 (2013
71. Verdine, G. L., & Walensky, L. D. The challenge of drugging undruggable targets in cancer: lessons learned from targeting BCL-2 family members. Clin. Cancer Res. 13, 7264-7270 (2007
72. List, A. F., Vardiman, J., Issa, J. P., & DeWitte, T. M. Myelodysplastic syndromes. Hematology Am. Soc. Hematol. Educ. Program, 297-317 (2004
73. Griffiths, E. A., & Gore, S. D. Epigenetic therapies in MDS and AML. Adv. Exp. Med. Biol. 754, 253-283 (2013
74. Hagemann, S., Heil, O., Lyko, F., & Brueckner, B. Azacytidine and decitabine induce gene-specific and non-random DNA demethylation in human cancer cell lines. PLoS ONE 6, e17388 (2011
75. Pandiyan, K. et al. Functional DNA demethylation is accompanied by chromatin accessibility. Nucleic Acids Res. 41, 3973-3985 (2013
76. Glozak, M. A., & Seto, E. Histone deacetylases and cancer. Oncogene 26, 5420-5432 (2007
77. Gong, F., & Miller, K. M. Mammalian DNA repair: HATs and HDACs make their mark through histone acetylation. Mutat. Res. 750, 23-30 (2013
78. Camphausen, K., & Tofilon, P. J. Inhibition of histone deacetylation: a strategy for tumor radiosensitization. J. Clin. Oncol. 25, 4051-4056 (2007
79. Miller, K. M. et al. Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining. Nature Struct. Mol. Biol. 17, 1144-1151 (2010
80. Cameron, E. E., Bachman, K. E., Myohanen, S., Herman, J. G., & Baylin, S. B. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nature Genet. 21, 103-107 (1999
81. Belinsky, S. A. et al. Combination therapy with vidaza and entinostat suppresses tumor growth and reprograms the epigenome in an orthotopic lung cancer model. Cancer Res. 71, 454-462 (2011
82. Okada, Y. et al. hDOT1L links histone methylation to leukemogenesis. Cell 121, 167-178 (2005
83. Daigle, S. R. et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 20, 53-65 (2011
84. Bernt, K. M. et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 20, 66-78 (2011
85. Grembecka, J. et al. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nature Chem. Biol. 8, 277-284 (2012
86. Cao, F. et al. Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia. Mol. Cell 53, 247-261 (2014
87. Varambally, S. et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419, 624-629 (2002
88. Takawa, M. et al. Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker. Cancer Sci. 102, 1298-1305 (2011
89. Morin, R. D. et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nature Genet. 42, 181-185 (2010
90. Morin, R. D. et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476, 298-303 (2011
91. Pasqualucci, L. et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nature Genet. 43, 830-837 (2011
92. McCabe, M. T. et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-Activating mutations. Nature 492, 108-112 (2012
93. Filippakopoulos, P. et al. Selective inhibition of BET bromodomains. Nature 468, 1067-1073 (2010
94. Nicodeme, E. et al. Suppression of inflammation by a synthetic histone mimic. Nature 468, 1119-1123 (2010). References 93 and 94 describe unprecedented examples of targeting the BET bromodomain family of epigenetic readers with small molecules.
95. Chung, C. W. et al. Discovery and characterization of small molecule inhibitors of the BET family bromodomains. J. Med. Chem. 54, 3827-3838 (2011
96. Dawson, M. A. et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478, 529-533 (2011
97. Delmore, J. E. et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146, 904-917 (2011
98. Mertz, J. A. et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc. Natl Acad. Sci. USA 108, 16669-16674 (2011
99. Zuber, J. et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478, 524-528 (2011
100. Hnisz, D. et al. Super-enhancers in the control of cell identity and disease. Cell 155, 934-947 (2013
101. Whyte, W. A. et al. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell 153, 307-319 (2013
102. Chapuy, B. et al. Discovery and characterization of super-enhancer-Associated dependencies in diffuse large B cell lymphoma. Cancer Cell 24, 777-790 (2013
103. Loven, J. et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 153, 320-334 (2013
104. Matzuk, M. M. et al. Small-molecule inhibition of BRDT for male contraception. Cell 150, 673-684 (2012
105. Jin, C. et al. Chem-seq permits identification of genomic targets of drugs against androgen receptor regulation selected by functional phenotypic screens. Proc. Natl Acad. Sci. USA 111, 9235-9240 (2014
106. Larrieu, D., Britton, S., Demir, M., Rodriguez, R., & Jackson, S. P. Chemical inhibition of NAT10 corrects defects of laminopathic cells. Science 344, 527-532 (2014
107. Charrier, J. D. et al. Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents. J. Med. Chem. 54, 2320-2330 (2011
108. Dawson, M. A. et al. JAK2 phosphorylates histone H3Y41 and excludes HP1? from chromatin. Nature 461, 819-822 (2009
109. Hickson, I. et al. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res. 64, 9152-9159 (2004
110. Leahy, J. J. et al. Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries. Bioorg. Med. Chem. Lett. 14, 6083-6087 (2004
111. Konze, K. D. et al. An orally bioavailable chemical probe of the lysine methyltransferases EZH2 and EZH1. ACS Chem. Biol. 8, 1324-1334 (2013
112. Kim, M. S. et al. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res. 63, 7291-7300 (2003
113. Sharma, S. V. et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141, 69-80 (2010
114. Pommier, Y. Topoisomerase I inhibitors: camptothecins and beyond. Nature Rev. Cancer 6, 789-802 (2006
115. Aggarwal, M., Sommers, J. A., Shoemaker, R. H., & Brosh, R. M. Jr. Inhibition of helicase activity by a small molecule impairs Werner syndrome helicase (WRN) function in the cellular response to DNA damage or replication stress. Proc. Natl Acad. Sci. USA 108, 1525-1530 (2011
116. Nguyen, G. H. et al. A small molecule inhibitor of the BLM helicase modulates chromosome stability in human cells. Chem. Biol. 20, 55-62 (2013
117. Drygin, D. et al. Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth. Cancer Res. 71, 1418-1430 (2011
118. Bowers, E. M. et al. Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. Chem. Biol. 17, 471-482 (2010
119. Knutson, S. K. et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc. Natl Acad. Sci. USA 110, 7922-7927 (2013
120. Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913-917 (2005
121. Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921 (2005
122. Kreso, A. et al. Self-renewal as a therapeutic target in human colorectal cancer. Nature Med. 20, 29-36 (2014
123. Leung, J. W. et al. Nucleosome acidic patch promotes RNF168-And RING1B/BMI1-dependent H2AX and H2A ubiquitination and DNA damage signaling. PLoS Genet. 10, e1004178 (2014
124. Wang, L. et al. A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth. Nature Commun. 4, 2035 (2013
125. Kruidenier, L. et al. A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature 488, 404-408 (2012
126. Chen, J. et al. Selective and cell-Active inhibitors of the USP1/UAF1 deubiquitinase complex reverse cisplatin resistance in non-small cell lung cancer cells. Chem. Biol. 18, 1390-1400 (2011
127. Wagner, E. K., Nath, N., Flemming, R., Feltenberger, J. B., & Denu, J. M. Identification and characterization of small molecule inhibitors of a plant homeodomain finger. Biochemistry 51, 8293-8306 (2012
128. Pessetto, Z. Y., Yan, Y., Bessho, T., & Natarajan, A. Inhibition of BRCT(BRCA1)-phosphoprotein interaction enhances the cytotoxic effect of olaparib in breast cancer cells: a proof of concept study for synthetic lethal therapeutic option. Breast Cancer Res. Treat. 134, 511-517 (2012
129. Brueckner, B. et al. Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. Cancer Res. 65, 6305-6311 (2005).